An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

Table 4 Peak and trough concentration data and estimates of amikacin pharmacokinetic parameters

Patient profile	Dose	Dosage interval	Cpmax	Cpmin	t_1/2	k	TBC	V_d
Patient profile	(mg)	(h)	(mg l^-1)	(mg l^-1)	(h)	(h^-1)	(l h^-1)	(l)
P1A	900	24	31.3	3	6.80	0.102	2.858	28.03
P1B	900	24	33.8	4	7.63	0.091	2.583	28.44
P1C	1100	24	35.7	6.2	9.10	0.076	2.579	33.89
Mean					7.84	0.090	2.674	30.12
P2A	300	19	7.6	1.8	8.66	0.080	3.096	38.69
P2B	1500	24	50.2	2.8	5.52	0.125	3.761	29.97
P2C	1500	24	48.5	5.4	7.42	0.093	2.987	31.98
P2D	1500	29	49.4	5	8.47	0.082	2.719	33.24
P2E	1500	32	55.9	6.1	9.70	0.071	2.062	28.85
P2F	1500	29	53.8	7	9.51	0.073	2.239	30.74
Mean					8.21	0.088	2.811	32.25
CVVHDF Stopped P2G	1500	53.5	68.3	16.1	25.18	0.028	0.668	24.26
P3A	1500	24	44.9	2.8	5.74	0.121	3.911	32.42
P3B	1500	24	42.4	1.9	5.13	0.135	4.923	36.46
P3C	1500	24	46.5	2.1	5.26	0.132	4.278	32.46
Mean					5.38	0.129	4.371	33.78
P4A	600	12	16.2	4	5.45	0.127	4.563	35.88
P4B	600	12	23.4	5	5.16	0.134	3.961	29.52
Mean					5.31	0.131	4.262	32.70
P5A	1500	24	48.2	2.1	5.09	0.136	4.099	30.08
P5B	1500	25	52.4	2.4	5.39	0.128	3.701	28.81
P5C	1500	28	54.4	2.5	5.29	0.131	3.649	27.84
P5D	1500	28	55.8	2.5	6.03	0.115	3.137	27.28
Mean					5.45	0.128	3.646	28.50
Overall mean*					6.74	0.109	3.39	31.4
Standard deviation					1.69	0.025	0.82	3.27
Median					5.88	0.118	3.39	30.4

* Excluding profile P2G.
Cpmax: maximum serum concentration Cpmin: minimum serum concentration.
t_1/2: half life. V_d: volume of distribution. TBC: Total body clearance. k: elimination rate constant.
PX (1–5): patients 1–5. PXA-PXE: first (A) to fifth (E) dosing interval during which serum concentration data was collected for patient PX.

ISSN: 2050-6511